69981-00-6

Usage

Uses

Used in Pharmaceutical Industry:
Pyrido[3,4-d]pyriMidin-4(1H)-one, 5,6,7,8-tetrahydro-7-(phenylMethyl)-, Monohydrochloride is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique chemical structure allows it to serve as a building block in the development of new therapeutic agents, potentially targeting a range of medical conditions.
Used in Research Applications:
In the field of scientific research, Pyrido[3,4-d]pyriMidin-4(1H)-one, 5,6,7,8-tetrahydro-7-(phenylMethyl)-, Monohydrochloride is employed as a research reagent. It aids in the investigation of chemical reactions, synthesis processes, and the exploration of its potential biological activities, contributing to the advancement of knowledge in chemistry and related disciplines.

Upstream product

• 62458-96-2 7-benzyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one 
• 3473-63-0 formamidine acetic acid 
• 52763-21-0 ethyl 1-benzyl-3-oxopiperidine-4-carboxylate hydrochloride 

Downstream Products

• 441064-74-0 7-benzyl-4-morpholin-4-yl-5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidine 
• 192869-80-0 7-Benzyl-4-chloro-5,6,7,8-tetrahydro-1,3,7-triazanaphthalene 
• 1255099-37-6 7-benzyl-4-chloro-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine trihydrochloride 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF

Compounds are disclosed that have a formula represented by the following (I), the compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including

Process development and scale-up of a selective α1- adrenoceptor antagonist

A synthetic route to a potent and selective α-1-adrenergic receptor antagonist has been developed and demonstrated in a pilot plant. The route has been used in two pilot plant campaigns and has produced RO3203546 in 2.3 and 12.0 kg batch sizes. The first pilot plant campaign focused primarily on the end-game of the process with particular emphasis on the development of a method to isolate the active pharmaceutical ingredient (API). The second pilot plant campaign allowed front-end process improvements to be demonstrated. The reiterative process improvements resulted in an economical process with improved throughput and product quality when compared to the original discovery synthesis.